| Name | Title | Contact Details |
|---|
Nivalis Therapeutics (formerly N30Pharma) is developing a novel class of disease modifying therapies that preserve intracellular GSNO (S-nitrosoglutathione), a key regulator of organ repair, regeneration, and healing. The Company’s lead program is focused on cystic fibrosis. As the body’s primary reservoir of nitric oxide (NO), GSNO plays a pivotal role in NO signaling. Decreased GSNO levels are associated with inflammatory lung disease, and with increased activity of GSNOR (GSNO reductase), the primary catabolizing enzyme of GSNO. Nivalis Therapeutics has developed a broad portfolio of proprietary, potent, small molecule inhibitors of GSNOR that have been shown to preserve endogenous GSNO levels and to be effective in “gold-standard” models of inflammatory lung disease. Nivalis Therapeutics is located in Boulder, Colorado.
At California Hospital Association (CHA), we collaborate with our members to provide strong and effective representation and advocacy to advance the interests of California hospitals, patients and communities. CHA is a trusted resource, working with members to achieve legislative, regulatory, and legal accomplishments at the state and federal level. Based in Sacramento, CHA is the statewide leader representing the interests of more than 400 hospitals and health systems in California.
Progressive Home Health Care is a Wichita, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
To improve the health status of the communities we serve through compassionate, high quality, accessible and cost effective care. We value those who provide our care and those who receive our care. We accomplish this through partnership, dedication, service, quality and stewardship.
Biolux Research Ltd. is a world leader in the development of innovative Light Accelerated™ technology and products for use in orthodontics, implantology, and other dentistry markets.